



1/4

FIGURE 1


XRPD data for Example 9 amorphous solid dispersion

2/4

FIGURE 2


Animals with subcutaneous KCL-22 xenografts received daily treatment with Example 9. Dose-dependent antitumor activity was demonstrated.

3/4

FIGURE 3

KCL-22 cells were grown as sub-cutaneous xenografts and four animals were dosed with 75mg/kg Nilotinib BID (twice daily). When tumors developed resistance to treatment with Nilotinib the dosing was changed to 30mg/kg Example 9 BID. The treatment of nilotinib resistant tumors with Example 9 led to regression of the tumors. Each line represents a separate animal.

4/4

FIGURE 4

Animals with subcutaneous KCL-22 xenografts were dosed with a combination of 30mg/kg Example 9 BID and 75mg/kg Nilotinib BID. Each line represents a separate animal. Complete tumor regression was seen in all animals and was maintained to the end of the study.